Who
Arthur S. Kirsch
Director
Company insider
Files Form 4 as: Director, Evommune; Director, Atea Pharmaceuticals; Director, Liquidia; Director, Kadmon Holdings; Director, Liquidia Technologies; Director, Aralez Pharmaceuticals; Director, Pozen Inc /nc; Director, Immunomedics.
In numbers
- Trades disclosed
- 104
- Buys
- 12
- Sells
- 8
- Bought
- $844K
- Sold
- $3.7M
- Companies
- 8
- Companies where not an officer
- 8
- First trade
- 3 Jan 2006
- Last trade
- 7 Jul 2026
- Last filed
- 8 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Jul 2026filed 8 Jul 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Bought | $133K10,000 at $13.30 | filing |
| 7 Jul 2026filed 8 Jul 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Bought | $133K10,000 at $13.30 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,700 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Code A | —5,882 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Code A | —5,882 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $548K10,000 at $54.80 | filing |
| 3 Jun 2026filed 3 Jun 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $548K10,000 at $54.80 | filing |
| 2 Jun 2026filed 3 Jun 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $280K5,000 at $56.00 | filing |
| 2 Jun 2026filed 3 Jun 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $280K5,000 at $56.00 | filing |
| 2 Jun 2026filed 3 Jun 2026 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,673 at $0.00 | filing |
| 2 Jun 2026filed 3 Jun 2026 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,673 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $903K15,000 at $60.22 | filing |
| 1 Jun 2026filed 3 Jun 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $903K15,000 at $60.22 | filing |
| 5 Nov 2025filed 7 Nov 2025 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,960 at $0.00 | filing |
| 17 Jun 2025filed 20 Jun 2025 | LQDA LiquidiaBiotechnology | SEC FORM 4 Code A | —18,396 at $0.00 | filing |
| 20 Feb 2025filed 24 Feb 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —164,800 at $0.00 | filing |
| 20 Jun 2024filed 24 Jun 2024 | LQDA LiquidiaBiotechnology | SEC FORM 4 Code A | —20,359 at $0.00 | filing |
News
Liquidia (NASDAQ:LQDA) Stock Sees Heavy Call Option BuyingLQDA · dailypolitical.com · 14 Oct 2026Evommune (NYSE:EVMN) Stock Bumped Up to "Hold" by UBS GroupEVMN · tickerreport.com · 14 Oct 2026Evommune (NYSE:EVMN) Upgraded at UBS GroupEVMN · dailypolitical.com · 14 Oct 2026Insider Selling: Liquidia (NASDAQ:LQDA) General Counsel Sells $389,948.16 in StockLQDA · themarketsdaily.com · 14 Oct 2026Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAHLQDA · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Arthur S. Kirsch; 5 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.